Yuan Jingzhen, Pandol Stephen J
West Los Angeles VA Healthcare Center, UCLA/VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Bldg 258, Rm 340, Los Angeles, CA, 90073, USA.
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
J Gastroenterol. 2016 Jul;51(7):651-9. doi: 10.1007/s00535-016-1175-3. Epub 2016 Feb 15.
Acute pancreatitis is a serious medical disorder with no current therapies directed to the molecular pathogenesis of the disorder. Inflammation, inappropriate intracellular activation of digestive enzymes, and parenchymal acinar cell death by necrosis are the critical pathophysiologic processes of acute pancreatitis. Thus, it is necessary to elucidate the key molecular signals that mediate these pathobiologic processes and develop new therapeutic strategies to attenuate the appropriate signaling pathways in order to improve outcomes for this disease. A novel serine/threonine protein kinase D (PKD) family has emerged as key participants in signal transduction, and this family is increasingly being implicated in the regulation of multiple cellular functions and diseases.
This review summarizes recent findings of our group and others regarding the signaling pathway and the biological roles of the PKD family in pancreatic acinar cells. In particular, we highlight our studies of the functions of PKD in several key pathobiologic processes associated with acute pancreatitis in experimental models.
Our findings reveal that PKD signaling is required for NF-κB activation/inflammation, intracellular zymogen activation, and acinar cell necrosis in rodent experimental pancreatitis. Novel small-molecule PKD inhibitors attenuate the severity of pancreatitis in both in vitro and in vivo experimental models. Further, this review emphasizes our latest advances in the therapeutic application of PKD inhibitors to experimental pancreatitis after the initiation of pancreatitis.
These novel findings suggest that PKD signaling is a necessary modulator in key initiating pathobiologic processes of pancreatitis, and that it constitutes a novel therapeutic target for treatments of this disorder.
急性胰腺炎是一种严重的医学病症,目前尚无针对该病症分子发病机制的治疗方法。炎症、消化酶的不适当细胞内激活以及实质腺泡细胞坏死是急性胰腺炎的关键病理生理过程。因此,有必要阐明介导这些病理生物学过程的关键分子信号,并开发新的治疗策略来减弱适当的信号通路,以改善该疾病的治疗效果。一种新的丝氨酸/苏氨酸蛋白激酶D(PKD)家族已成为信号转导的关键参与者,并且该家族越来越多地参与多种细胞功能和疾病的调节。
本综述总结了我们团队和其他团队关于PKD家族在胰腺腺泡细胞中的信号通路和生物学作用的最新发现。特别是,我们重点介绍了我们在实验模型中对PKD在与急性胰腺炎相关的几个关键病理生物学过程中的功能研究。
我们的研究结果表明,在啮齿动物实验性胰腺炎中,PKD信号是核因子κB激活/炎症、细胞内酶原激活和腺泡细胞坏死所必需的。新型小分子PKD抑制剂在体外和体内实验模型中均能减轻胰腺炎的严重程度。此外,本综述强调了我们在胰腺炎发作后将PKD抑制剂应用于实验性胰腺炎治疗方面的最新进展。
这些新发现表明,PKD信号是胰腺炎关键起始病理生物学过程中的必要调节因子,并且它构成了治疗该病症的新治疗靶点。